There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | ADEM ALBAYRAK |
| Institution: | Alzheon |
| Department: | Operations |
| Country: | |
| Proposed Analysis: | We seek to analyze the longitudinal change/decline in episodic memory (i.e. RAVLT clinical memory test) in MCI and mild AD patients stratified by APOE4 genotype. We also plan to evaluate impact of factors such as demographics or baseline biomarkers and their role in how they might affect clinical progression. These data are expected to yield valuable clinical information that will help the understanding of how changes in episodic memory progresses over time based on APOE4 status and will be used to guide future clinical AD efficacy trials that employ this clinical memory test. It is expected that the results from this analysis will published in leading peer reviewed clinical AD journals and/or clinical AD conferences. |
| Additional Investigators | |
| Investigator's Name: | John Hey |
| Proposed Analysis: | We seek to analyze the longitudinal change/decline in episodic memory (i.e. RAVLT clinical memory test) in MCI and mild AD patients stratified by APOE4 genotype. We also plan to evaluate impact of factors such as demographics or baseline biomarkers and their role in how they might affect clinical progression. These data are expected to yield valuable clinical information that will help the understanding of how changes in episodic memory progresses over time based on APOE4 status and will be used to guide future clinical AD efficacy trials that employ this clinical memory test. It is expected that the results from this analysis will be published in leading peer reviewed clinical AD journals and/or clinical AD conferences. |
| Investigator's Name: | Daniel Lancour |
| Proposed Analysis: | We seek to analyze the longitudinal change/decline in episodic memory (i.e. RAVLT clinical memory test) in MCI and mild AD patients stratified by APOE4 genotype. We also plan to evaluate impact of factors such as demographics or baseline biomarkers and their role in how they might affect clinical progression. These data are expected to yield valuable clinical information that will help the understanding of how changes in episodic memory progresses over time based on APOE4 status and will be used to guide future clinical AD efficacy trials that employ this clinical memory test. It is expected that the results from this analysis will be published in leading peer reviewed clinical AD journals and/or clinical AD conferences. |
| Investigator's Name: | Erwan de Naurois |
| Proposed Analysis: | RWD analysis of patient progression |
